AUTL · Autolus Therapeutics
AI read · Good for AUTL
The AI's read
More treatment centers can give more doctors access to obe-cel, and the company says doctors’ positive experiences are helping sales grow. Production improvements also helped raise the share of sales left after production costs. Research spending rose as clinical trials expanded, adding to costs. But stronger sales, more efficient production, and cash expected to last into Q2 2028 make the company’s progress favorable overall.